CGON Stock Summary and Trading Ideas (CG Oncology | NASDAQ:CGON)

CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.

CG Oncology trades on the NASDAQ stock market under the symbol CGON.

As of October 16, 2026, CGON stock price declined to $59.85 with 1,044,007 million shares trading.

CGON has a beta of 0.89, meaning it tends to be less sensitive to market movements. CGON has a correlation of 0.05 to the broad based SPY ETF.

CGON has a market cap of $5.31 billion. This is considered a Mid Cap stock.

Last quarter CG Oncology reported $1 million in Revenue and -$.90 earnings per share. This beat revenue expectation by $325,208 and missed earnings estimates by -$.25.

The top ETF exchange traded funds that CGON belongs to (by Net Assets): VTI, VB, IWM, XBI, VBK.

CGON has outperformed the market in the last year with a return of +43.0%, while the SPY ETF gained +16.7%. However, in the most recent history, CGON shares have underperformed the stock market with its stock returning -13.9% in the last 3 month period and -11.2% for the last 2 week period, while SPY has returned +1.9% and -0.8%, respectively.

CGON support price is $59.78 and resistance is $63.94 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CGON shares will trade within this expected range on the day.